← back to search

Michael Durante

University of Miami Health System · US
Area of research
Hematology · Ophthalmology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Ocular Oncology and Treatments, Protein Degradation and Inhibitors, and Cancer Genomics and Diagnostics.
h-index
18
citations
2,431
works
138
NIH funding
primary concept
Medicine
email

Recent publications

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Blood 2025cited by 12position: middledoi
Genomics Define Malignant Transformation in Myeloma Precursor Conditions
Journal of Clinical Oncology 2025cited by 6position: middledoi
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Blood Cancer Discovery 2025cited by 4position: middledoi
Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Blood Cancer Discovery 2025cited by 2position: middledoi
Early genetic evolution of driver mutations in uveal melanoma
Nature Communications 2025cited by 2position: middledoi
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Journal of Clinical Oncology 2024cited by 116position: middledoi
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Blood 2024cited by 58position: middledoi
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma
Clinical Cancer Research 2024cited by 16position: middledoi
Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Blood 2024cited by 8position: middledoi
CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 2position: middledoi
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Nature Medicine 2023cited by 305position: middledoi
PRAME induces genomic instability in uveal melanoma
Oncogene 2023cited by 25position: middledoi
The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma
Blood 2023cited by 14position: middledoi
RB1 loss triggers dependence on ESRRG in retinoblastoma
Science Advances 2022cited by 20position: middledoi
HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
Cancer Gene Therapy 2022cited by 10position: middledoi
Uphyloplot2: visualizing phylogenetic trees from single-cell RNA-seq data
BMC Genomics 2021cited by 41position: middledoi
Multiregional genetic evolution of metastatic uveal melanoma
npj Genomic Medicine 2021cited by 11position: middledoi
Single-cell analysis reveals new evolutionary complexity in uveal melanoma
Nature Communications 2020cited by 476position: firstdoi
Single-cell analysis of olfactory neurogenesis and differentiation in adult humans
Nature Neuroscience 2020cited by 249position: firstdoi
A novel cardiomyogenic role for Isl1 <sup>+</sup> neural crest cells in the inflow tract
Science Advances 2020cited by 20position: middledoi
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers
Science Advances 2019cited by 86position: middledoi
Punctuated evolution of canonical genomic aberrations in uveal melanoma
Nature Communications 2018cited by 196position: middledoi
Drug and disease signature integration identifies synergistic combinations in glioblastoma
Nature Communications 2018cited by 109position: middledoi
Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
Blood 2017cited by 167position: middledoi
Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas
Oncotarget 2016cited by 124position: middledoi
Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation
Oncogene 2015cited by 138position: middledoi
Conversion Strategy Using an Expanded Genetic Alphabet to Assay Nucleic Acids
Analytical Chemistry 2013cited by 31position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

J. William Harbour · The University of Texas Southwestern Medical Center13 papers (2016–2023)Matthew G. Field · Minnesota Eye Consultants6 papers (2016–2023)Ola Landgren · Miami University5 papers (2023–2025)Francesco Maura · Palmetto General Hospital5 papers (2023–2025)Benjamin Diamond · University of Miami5 papers (2023–2025)Christina L. Decatur · University of Miami5 papers (2016–2023)Bachisio Ziccheddu · University of Miami Health System5 papers (2023–2025)Daniel A. Rodriguez · University of California, Berkeley5 papers (2019–2023)Marios Papadimitriou · University of Miami4 papers (2024–2025)Jeffim N. Kuznetsov · Sylvester Comprehensive Cancer Center3 papers (2016–2020)Sungwoo Ahn · Ontario Institute for Cancer Research3 papers (2023–2025)Holly Lee · Ontario Institute for Cancer Research3 papers (2023–2025)Paola Neri · Ontario Institute for Cancer Research3 papers (2023–2025)Nizar J. Bahlis · University of Calgary3 papers (2023–2025)Gareth J. Morgan · Amyloidosis Foundation2 papers (2024–2025)Margaret I. Sanchez · University of Miami2 papers (2020–2023)David Jung · University of South Carolina2 papers (2023–2024)Jeffim N. Kuznetsoff · University of Miami2 papers (2022–2023)Kylee Maclachlan · Memorial Sloan Kettering Cancer Center2 papers (2024–2025)Anthony Cruz · University of Tennessee Health Science Center2 papers (2021–2023)